Get the Stockscreener App
2.85
0.71%
0.02
Orchestra Biomed Holdings Inc stock is traded at $2.85, with a volume of 79,922.
It is up +0.71% in the last 24 hours and down -4.04% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$2.83
Open:
$2.8
24h Volume:
79,922
Relative Volume:
0.23
Market Cap:
$109.57M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-1.90
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+4.78%
1M Performance:
-4.04%
6M Performance:
-49.38%
1Y Performance:
-57.27%
1-Day Range:
$2.76
$2.88
1-Week Range:
$2.7205
$3.0181
52-Week Range:
$2.37
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.86 | 104.59M | 2.76M | -49.12M | -46.21M | -1.50 |
|
ONC
Beone Medicines Ltd Adr
|
245.92 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.90 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.53 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.50 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stake Increased by Northern Trust Corp - Defense World
Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN
How To Trade (OBIO) - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Raises Position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FY2026 Earnings Estimate for OBIO Issued By Chardan Capital - Defense World
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Target | OBIO Stock News - GuruFocus
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - The Manila Times
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orchestra Biomed Holdings Inc Stock (OBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 29 '25 |
Buy |
2.53 |
50,000 |
126,500 |
8,256,163 |
| Aryeh Jason | Director |
Dec 27 '24 |
Option Exercise |
4.30 |
11,700 |
50,310 |
80,060 |
| Hochman David P | See Remarks |
Dec 23 '24 |
Buy |
4.66 |
4,000 |
18,640 |
579,498 |
| Taylor Andrew Lawrence | Chief Financial Officer |
Dec 19 '24 |
Buy |
4.83 |
1,000 |
4,830 |
344,960 |
| Hochman David P | See Remarks |
Dec 18 '24 |
Buy |
4.91 |
5,000 |
24,550 |
575,498 |
| Hochman David P | See Remarks |
Sep 25 '24 |
Buy |
4.75 |
7,500 |
35,630 |
335,002 |
| Hochman David P | See Remarks |
Sep 24 '24 |
Buy |
4.91 |
2,500 |
12,275 |
570,498 |
| Sherman Darren | See Remarks |
Sep 09 '24 |
Sale |
5.48 |
6,804 |
37,286 |
772,691 |
| Sherman Darren | See Remarks |
Sep 10 '24 |
Sale |
5.31 |
6,904 |
36,660 |
765,787 |
| Fain Eric S | Director |
Sep 06 '24 |
Sale |
5.64 |
2,000 |
11,280 |
44,810 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):